Literature DB >> 11463768

Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells.

Y Funakoshi1, T Ichiki, H Shimokawa, K Egashira, K Takeda, K Kaibuchi, M Takeya, T Yoshimura, A Takeshita.   

Abstract

Recently, it was shown that Rho-kinase plays an important role in blood pressure regulation. However, it is not known whether Rho-kinase is involved in atherogenesis. Monocyte chemoattractant protein-1 (MCP-1) is an important chemokine that regulates monocyte recruitment and atherogenesis. Therefore, we examined the role of Rho and Rho-kinase in the angiotensin (Ang) II-induced expression of MCP-1. Ang II dose- and time-dependently enhanced the expression of MCP-1 mRNA and the protein production in vascular smooth muscle cells. CV11974, an Ang II type 1 receptor (AT(1)-R) specific antagonist inhibited the enhancement of MCP-1 expression by Ang II, suggesting that the effect of Ang II is mediated by the AT(1)-R. Botulinum C3 exotoxin, a specific inhibitor of Rho, suppressed Ang II-induced MCP-1 production. To examine the role of Rho-kinase in Ang II-induced MCP-1 expression, we used adenovirus-mediated overexpression of the dominant negative mutant of Rho-kinase (AdDNRhoK) or Y-27632, a specific inhibitor of Rho-kinase. Both AdDNRhoK and Y-27632 strongly inhibited Ang II-induced MCP-1 expression. Although inhibition of extracellular signal-regulated protein kinase (ERK) by PD 098,059 also inhibited Ang II-induced MCP-1 expression, Y-27632 did not affect Ang II-induced activation of ERK. These results indicate that Rho-kinase plays a critical role in Ang II-induced MCP-1 production independent of ERK. The Rho-Rho-kinase pathway may be a novel target for the inhibition of Ang II signaling and the treatment of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11463768     DOI: 10.1161/01.hyp.38.1.100

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  37 in total

Review 1.  Monocyte chemoattractant protein-1: a key mediator of angiotensin II-induced target organ damage in hypertensive heart disease?

Authors:  Jia L Zhuo
Journal:  J Hypertens       Date:  2004-03       Impact factor: 4.844

Review 2.  Rho kinase (ROCK) inhibitors.

Authors:  James K Liao; Minoru Seto; Kensuke Noma
Journal:  J Cardiovasc Pharmacol       Date:  2007-07       Impact factor: 3.105

Review 3.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.

Authors:  M Oka; K A Fagan; P L Jones; I F McMurtry
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

Review 4.  Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis.

Authors:  Naoki Sawada; James K Liao
Journal:  Antioxid Redox Signal       Date:  2013-09-24       Impact factor: 8.401

Review 5.  Rho kinase as a therapeutic target in cardiovascular disease.

Authors:  Michelle Surma; Lei Wei; Jianjian Shi
Journal:  Future Cardiol       Date:  2011-09

Review 6.  The role of angiotensin II in regulating vascular structural and functional changes in hypertension.

Authors:  Rhian M Touyz
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

Review 7.  Botulinum toxins--cause of botulism and systemic diseases?

Authors:  H Böhnel; F Gessler
Journal:  Vet Res Commun       Date:  2005-05       Impact factor: 2.459

8.  Angiotensin II induces apoptosis of human pulmonary microvascular endothelial cells in acute aortic dissection complicated with lung injury patients through modulating the expression of monocyte chemoattractant protein-1.

Authors:  Zhiyong Wu; Feifeng Dai; Wei Ren; Huagang Liu; Bowen Li; Jinxing Chang
Journal:  Am J Transl Res       Date:  2016-01-15       Impact factor: 4.060

Review 9.  Does it matter whether or not a lipid-lowering agent inhibits Rho kinase?

Authors:  James K Liao
Journal:  Curr Atheroscler Rep       Date:  2007-11       Impact factor: 5.113

Review 10.  Nuclear factor-kappaB as a hormonal intracellular signaling molecule: focus on angiotensin II-induced cardiovascular and renal injury.

Authors:  Xiao C Li; Jia L Zhuo
Journal:  Curr Opin Nephrol Hypertens       Date:  2008-01       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.